Nov 3 2011
"Scientists at the University of California, Berkeley, and the biotech start-up Amyris [have] developed a process to manufacture artemisinin, a crucial ingredient in first-line malaria drugs that until now had to be extracted from a natural crop called sweet wormwood," PBS NewsHour reports. "The new semi-synthetic artemisinin ... successfully entered the production phase through a public-private partnership with the drug company Sanofi-Aventis earlier this year" and "will hit the market beginning in 2012," according to NewsHour. Olusoji Adeyi, who runs the affordable malaria medication program at the Global Fund to Fight AIDS, Tuberculosis and Malaria, said the new formulation of artemisinin will help make better quality malaria treatments more affordable and increase access, NewsHour reports (Miller, 10/31).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |